BULLETIN: March 30, 3017 – from the National Leiomyosarcoma Foundation (NLMSF)
Today, Oncologists from around the world will gather in Madrid April l for a second edition of the International Congress Soft Tissue Sarcoma: Evidence and Experience. This conference will cove the following topics:
– sharing the latest developments in the management of the different types of soft tissue sarcoma (STS)
– the differences observed in the administration of the various therapeutic options available and especially the important role recommended for patients in the treatment decision making process.
– the treatment options for the most common STS subtypes – Leiomyosarcomas and Liposarcomas.
The diversity of sarcoma subtypes presents a challenge in terms of the type of treatment to best combat the disease.
– Identifying the treatment goal – identification of a therapeutic goal according to the state of the disease – analyzing
which approach to take for patients following surgery or for those who have already been treated previously.
– The patient’s quality of life at the heart of the therapy – Dr. Robin Jones will lead this discussion to address quality of key issue in the evolution of sarcomas.
– Quality of life assessment for each patient, measured throughout the treatment relative to localized and metastatic
sarcomas – establishing the results in such patients.
– Discussion of YonLife – a study of a randomized prospective trial studying patients treated with Trabectedin, and the impact on quality of life based on being cared for by a multidisciplinary team or a conventional team. This study will be completed in December, and will measure whether a change occurs in the measurement o the quality of life in patients after nine weeks of treatment.
– Patients’ decision-making power – in line with the importance of quality of life during the treatment of sarcomas
Analysis of how the disease is experienced from the patient’s perspective.
The international Conference bringing together oncologists from around the world will also discuss this:
“It has been noted that the major problem for patients is that in many cases they cannot receive treatment from a sarcoma specialist because they lack access to the networks of health professionals and centers that specialize in this.” – from Pr.Le Cesne, Chief Herault Medical Oncology Unit.
Pr. Le Cesne underlines the importance of decisions about treatment to be taken by a multidisciplinary team that includes the patient for all stages of the disease.
Further results from this conference will be provided . . . .the topics are so very important to us all and this is very exciting to know that such topics are the platform for global discussion, especially in highlighting Leiomyosaromas and Liposarcomas. The YonLife study will be monitored and more information will follow from the NLMSF.
The National LeioMyoSarcoma Foundation (NLMSF) is a 501(c)(3) Non-Profit Charitable Organization and a member of the GuideStar Exchange.
National LeioMyoSarcoma Foundation – NLMSF
2843 E. Grand River Avenue – #230 East Lansing, MI 48823
Sarcoma Coalition – We are here for you.
The Sarcoma Coalition brings together advocacy groups throughout the United States, to build bridges of collaborative resource advocacy and support and Sarcoma Research Community alliances.
By working together, the Sarcoma Coalition members extend their advocacy strength and provide a united presence for patients and their families/caregivers.
“Achieving More Together!”
Information provided on the NLMSF website and Facebook page as well as any referenced information links are provided for informational purposes only and do not represent medical advice or opinions. All information provided has a referenced source indicated for further access to the information being provided to followers. Followers are responsible for interactions with this website, the Facebook page, and any links relative to the medical information offered/posted.
Q & A Patient / Clinician Disclaimer:
Please be advised that only general questions may be directed to a volunteer clinician, and to only expect a general response – one that does not take the place of your medical care team/oncologist’s guidance and care.
Please do not include personal information such as your full name, date of birth, personal medical information in any emails sent through the Foundation’s open Facebook group or webpage on its website. No one can diagnose your condition from email or any other written communication and communication via the Foundation’s Facebook group / website cannot replace the relationship you have with your health care provider(s).